ADVA
10.9.2020 09:02:04 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that Alsard Fiber is utilizing its FSP 3000 OLS technology to provide extremely resilient, high-capacity services across Iraq. The solution enables the country’s fastest-growing IP service wholesaler to improve quality, avoid downtime and deliver on high-value SLAs for its ISP, telecom, government and business customers. Protected by ADVA’s multi-degree ROADMs, which automatically reroute traffic in the case of fiber breaks, the new infrastructure is Iraq’s only network with end-to-end redundancy for maximum availability. What’s more, Alsard Fiber’s infrastructure is assured by ADVA ALM fiber monitoring technology, empowering it to remotely identify areas of degradation and rapidly locate faults, boosting reliability and significantly reducing cost.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005037/en/
“What we needed from this deployment was high capacity, resilience and the ability to guarantee our stringent SLAs. ADVA’s technology gives us a network that delivers on all counts. Now we can support our huge customer base with a redundant, monitored and robustly protected fiber backbone able to provide fast and reliable services and ready to withstand the most difficult environments,” said Firya Mohammad Ali, CEO, Alsard Fiber. “We’ve invested heavily in our fiber plant. Our network stretches thousands of kilometers across the country and this new solution helps us realize the full value of our assets. It enables us to boost efficiency and reliability and ensure the stability that our customers demand.”
Built on the ADVA FSP 3000, Alsard Fiber’s new network is designed for efficiency, ease of use and the highest levels of robustness. The fully redundant infrastructure leverages ADVA’s QuadFlex™ line cards and flexible ROADM technology so that traffic can be easily rerouted and new services remotely activated. With real-time fiber monitoring from ADVA’s ALM system , the solution saves Alsard Fiber time and money as faults can be resolved quickly with fewer truck rolls. Able to support a wide variety of data rates from 10Gbit/s to 40Gbit/s to 100Gbit/s, the modular solution also gives Alsard Fiber the flexibility to expand its network cost-effectively and without limits.
“Alsard Fiber is committed to providing its customers with highly reliable services and that requires extremely high levels of network survivability. Now, with our QuadFlex™ transponders and ultra-flexible ROADM layer, traffic can be instantly redirected in the event of any impairments. What’s more, with full network visibility, Alsard Fiber’s maintenance teams can take efficient, targeted action to head off faults before they become service issues,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Alsard Fiber now has the tools to provide robust and reliable services throughout Iraq. With our technology and support, it will continue to deliver on the promises of strict SLAs and ensure vital connectivity where it’s most needed.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005037/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
